ITEMS IN AFP WITH KEYWORD:
Coronary Artery Disease
Nov 1, 2017 Issue
Statins in Persons at Low Risk of Cardiovascular Disease [Medicine by the Numbers]
Despite the small reductions in nonfatal heart attacks and strokes, statins were not associated with a reduction in serious illness overall
Oct 1, 2017 Issue
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events [Medicine by the Numbers]
In patients who are stable one year post-MI, prolonged use of dual antiplatelet therapy may be an effective treatment to decrease major cardiac events and cardiovascular mortality.
Find out how to use exercise stress testing for risk stratification before surgery, which patients can be evaluated with testing alone, and which patients benefit from adjunctive imaging.
We are now flush with data about the effects of niacin in patients with elevated cholesterol levels. Despite its ability to raise high-density lipoprotein (HDL) serum cholesterol levels, it does not add additional mortality or morbidity benefit to statin treatment. Patients with diabetes mellitus ma...
Get the latest recommendations on when to discontinue antiplatelet therapy, beta blockers, statins, clonidine, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers before surgery.
Management of acute myocardial infarction begins with antiplatelet therapy and anticoagulation therapy, among other medications as appropriate. Learn which reperfusion strategies are recommended for patients with ST elevation myocardial infarction and non–ST elevation acute coronary syndrome.
Although chest pain is common with myocardial infarction, there are many noncardiac causes of chest pain. A diagnosis may not be possible based on initial presentation alone. The initial assessment includes evaluation of risk factors and presenting signs and symptoms, rapid electrocardiography, and serum cardiac troponin measurements.
Review the components of this multidisciplinary program that improves daily function and reduces mortality risk in persons with cardiovascular disease.
For the evaluation of chest pain in intermediate-risk patients, CCTA is comparable with myocardial perfusion imaging in its ability to select patients for invasive management. Both modalities are also similar when it comes to downstream resource use and adverse cardiovascular events. CCTA is associated with less radiation exposure.
Vorapaxar should be limited to select patients with a history of MI or peripheral arterial disease who desire additional treatment for the prevention of MI.